Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Vineela ParvathaneniMimansa GoyalNishant S KulkarniSnehal K ShuklaVivek GuptaPublished in: Pharmaceutical research (2020)
Nelfinavir, a lead HIV protease inhibitor can be repositioned as a NSCLC therapeutic through nanoparticulate delivery. Given its ability to induce apoptosis and efficient tumor penetration capability, NFV loaded PLGA nanoparticulate systems provide a promising delivery system in NSCLC treatment.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- drug delivery
- antiretroviral therapy
- brain metastases
- hiv infected
- hiv positive
- oxidative stress
- human immunodeficiency virus
- hepatitis c virus
- endoplasmic reticulum stress
- sars cov
- hiv aids
- hiv testing
- cell death
- cell cycle arrest
- emergency department
- drug release